Fezolinetant is a substrate of CYP1A2. Concomitant use of Fezolinetant with drugs that are weak, moderate, or strong CYP1A2 inhibitors, increase the plasma Cmax and AUC of Fezolinetant.
Fezolinetant is contraindicated in individuals using CYP1A2 inhibitors.
from FDA,2024.08